DK1333850T3 - Anvendelse af IL-13-inhibitorer til behandling af tumorer - Google Patents

Anvendelse af IL-13-inhibitorer til behandling af tumorer

Info

Publication number
DK1333850T3
DK1333850T3 DK01989341T DK01989341T DK1333850T3 DK 1333850 T3 DK1333850 T3 DK 1333850T3 DK 01989341 T DK01989341 T DK 01989341T DK 01989341 T DK01989341 T DK 01989341T DK 1333850 T3 DK1333850 T3 DK 1333850T3
Authority
DK
Denmark
Prior art keywords
subject
inhibitors
treat tumors
inhibitor
response
Prior art date
Application number
DK01989341T
Other languages
Danish (da)
English (en)
Inventor
Jay A Berzofsky
Debra D Donaldson
Masaki Terabe
So Matsui
Nancy Noben-Trauth
William E Paul
Original Assignee
Genetics Inst
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26981351&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1333850(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genetics Inst, Us Gov Health & Human Serv filed Critical Genetics Inst
Application granted granted Critical
Publication of DK1333850T3 publication Critical patent/DK1333850T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
DK01989341T 2000-10-20 2001-10-22 Anvendelse af IL-13-inhibitorer til behandling af tumorer DK1333850T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69360000A 2000-10-20 2000-10-20
US31818501P 2001-09-07 2001-09-07
PCT/US2001/051339 WO2002055100A2 (en) 2000-10-20 2001-10-22 Method and composition for inhibition of tumor growth and enhancing an immune response

Publications (1)

Publication Number Publication Date
DK1333850T3 true DK1333850T3 (da) 2008-12-01

Family

ID=26981351

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01989341T DK1333850T3 (da) 2000-10-20 2001-10-22 Anvendelse af IL-13-inhibitorer til behandling af tumorer

Country Status (8)

Country Link
EP (2) EP2027867A1 (enExample)
JP (2) JP2004537500A (enExample)
AT (1) ATE405282T1 (enExample)
AU (1) AU2002243443A1 (enExample)
DE (1) DE60135481D1 (enExample)
DK (1) DK1333850T3 (enExample)
ES (1) ES2311558T3 (enExample)
WO (1) WO2002055100A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050069546A1 (en) * 2003-09-30 2005-03-31 Yaron Ilan Educated NKT cells and their uses in the treatment of immune-related disorders
DK3718564T3 (da) 2003-12-23 2023-11-06 Genentech Inc Nye anti-IL-13-antistoffer og anvendelser
EP1720573A4 (en) * 2004-02-27 2008-04-02 Centocor Inc METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH IL-13
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
JP2008520684A (ja) 2004-11-17 2008-06-19 アブジェニックス・インコーポレーテッド Ｉｌ−１３に対する完全ヒトモノクローナル抗体
ES2523172T3 (es) * 2005-02-04 2014-11-21 Survac Aps Vacuna de péptido de survivina
KR101625961B1 (ko) 2006-09-08 2016-05-31 애브비 바하마스 리미티드 인터루킨-13 결합 단백질
US20120177668A1 (en) * 2009-07-06 2012-07-12 The Australian National University Immunomodulating compositions comprising interleukin 13 inhibitors and uses therefor
EP3447491A3 (en) 2010-12-16 2019-06-05 F. Hoffmann-La Roche AG Diagnosis and treatments relating to th2 inhibition
CH707030B1 (de) 2011-10-21 2015-03-13 Abbvie Inc Kombinationsbehandlung von DAAs zur Verwendung in der Behandlung von HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
ES2529143B1 (es) 2011-10-21 2015-10-26 Abbvie Inc. Combinación de al menos dos agentes antivirales de acción directa, ribavirina pero no interferón para uso de tratamiento del vhc
ES2915378T3 (es) 2013-09-13 2022-06-22 Hoffmann La Roche Procedimientos para detectar y cuantificar una proteína de célula huésped en líneas celulares
KR102571391B1 (ko) 2013-09-13 2023-08-29 제넨테크, 인크. 정제된 재조합 폴리펩티드를 포함하는 방법 및 조성물
US20170165364A1 (en) * 2014-02-21 2017-06-15 Idac Theranostics, Inc. Therapeutic agent for solid cancer
EP3448392A4 (en) 2016-04-28 2020-01-15 Emory University ALKYNOUS THERAPEUTIC NUCLEOTIDE AND NUCLEOSIDE COMPOSITIONS AND RELATED APPLICATIONS
TW202509218A (zh) * 2023-07-12 2025-03-01 亨利傑克森軍方醫學基金會 用於抑制自然殺手細胞之組合物及方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294322B1 (en) 1988-01-26 2001-09-25 The United States Of America As Represented By The Department Of Health And Human Services Multideterminant peptides that elicit helper T-lymphocyte cytotoxic T-lymphocyte and neutralizing antibody responses against HIV-1
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
WO1994004680A1 (en) * 1992-08-21 1994-03-03 Schering Corporation Human interleukin-13
US20010053371A1 (en) * 1999-01-07 2001-12-20 Waldemar Debinski Method for diagnosing, imaging, and treating tumors using restrictive receptor for interleukin 13
JPH09150569A (ja) 1995-11-29 1997-06-10 Riso Kagaku Corp 色画像形成用シート
GB9625899D0 (en) * 1996-12-13 1997-01-29 Glaxo Group Ltd Substances and their uses
US6013258A (en) 1997-10-09 2000-01-11 Zycos Inc. Immunogenic peptides from the HPV E7 protein
WO2000036103A1 (en) * 1998-12-14 2000-06-22 Genetics Institute, Inc. Cytokine receptor chain
AU2460600A (en) * 1999-02-10 2000-08-29 Mitsubishi Pharma Corporation Amide compounds and medicinal use thereof
EP1268794A2 (en) * 2000-04-07 2003-01-02 Heska Corporation Compositions and methods related to canine igg and canine il-13 receptors

Also Published As

Publication number Publication date
WO2002055100A2 (en) 2002-07-18
AU2002243443A8 (en) 2005-10-13
WO2002055100A3 (en) 2003-03-27
DE60135481D1 (de) 2008-10-02
ATE405282T1 (de) 2008-09-15
EP1333850B1 (en) 2008-08-20
EP1333850A2 (en) 2003-08-13
AU2002243443A1 (en) 2002-07-24
JP2004537500A (ja) 2004-12-16
ES2311558T3 (es) 2009-02-16
EP2027867A1 (en) 2009-02-25
JP2009046512A (ja) 2009-03-05
WO2002055100A9 (en) 2006-05-11

Similar Documents

Publication Publication Date Title
DK1333850T3 (da) Anvendelse af IL-13-inhibitorer til behandling af tumorer
ATE376434T1 (de) Injektionsgerät für mrna applikation
NZ524559A (en) 2-amino-2-alkyl-4 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors
ID26620A (id) Penghambatan kinase raf yang menggunakan urea-urea heterosiklik yang disubstitusi
DK1064027T3 (da) APO-2 Ligand-anti-her-2-antistofsynergier
EA200300348A1 (ru) Спирогетероциклические нитрилы, пригодные для применения в качестве обратимо действующих ингибиторов цистеиновых протеаз
DK1459766T3 (da) Adjuvanssammensætninger til forstærkning af immunresponser på polynukleotidbaserede vacciner
ATE542826T1 (de) Inhibitoren des hepatitis-c-virus
MY135721A (en) Amidino compounds useful as nitric oxide synthase inhibitors
CY1107649T1 (el) Συνδυασμος ο οποιος περιεχει ενα αντιφολικο αλας και παραγοντα ελαττωσης μεθυλομηλονικου οξεος
GEP20094751B (en) Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
YU28503A (sh) Humanizovana anti-lt-beta-r antitela
DE60318826D1 (de) Alkoxypyridinderivate
DK1255845T3 (da) Modificerede cytokiner til anvendelse i cancerterapi
ATE317693T1 (de) Substituierte stilbene mit gefässschädigender aktivität
SE9904674D0 (sv) Novel compounds
DK1485345T3 (da) Urokinaseinhibitorer, deres fremstilling og anvendelse
DE60121587D1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
IL139601A0 (en) Compositions and methods of modulating an immune response to an antigen
ATE424217T1 (de) Zusammensetzungen zur steigerung der effizienz von impfstoffen unter verwendung von chemokinen
DK1051187T3 (da) Behandling af follikulære lymfomer ved anvendelse af inhibitorer af lymfotoxin(LT)-syntesevejen
DE60122559D1 (de) Indolderivate als pde5-inhibitoren
CY1111289T1 (el) Συνθεσεις αναστολεων ογκου που περιεχουν νιτροακριδινη
DK1276722T3 (da) Naphthamidin-urokinaseinhibitorer
DK1565176T3 (da) Middel med ödelæggende virkning på maligne rumorer samt fremgangsmåde til fremstilling heraf